Risk factors for recurrent retinoblastoma after intravenous chemotherapy

Abstract

Purpose

To analyze the risk factors and estimate the risk period for tumor recurrence in intraocular retinoblastoma (RB).

Methods

Retrospective study of 60 RB patients.

Results

The mean age at presentation with RB was 16 months (median 11 months; range 1–84 months). Tumor was unilateral in 13 (22%) and bilateral in 47 (78%) patients. Of 83 eyes with intraocular RB, group B (n = 27; 33%) tumors were more common based on International Classification of Intraocular Retinoblastoma. All cases received intravenous chemotherapy as a primary treatment. Over a mean follow-up period of 57 months (median 38 months; range 12–185 months) post-primary treatment, 44 (73%) patients developed tumor recurrence. The mean interval between the completion of primary treatment and first tumor recurrence was 5 months (median 3 months; range 1–24 months). The total duration of treatment for complete tumor control including treatment of tumor recurrences was 20 months (median 19 months; 2–58 months). By multivariate analysis, the factors predictive of tumor recurrence were multiple tumors (p = 0.008) and retinal detachment (p = 0.003) at presentation. Kaplan–Meier estimate of tumor recurrence at 6 months, 1 year, 3 years, and 5 years was 20%, 31%, 68%, and 73%, respectively. There was no tumor recurrence beyond 5 years since primary treatment.

Conclusion

Multiple tumors and retinal detachment at presentation are risk factors for tumor recurrence in RB. Close follow-up is mandatory for at least 5 years since the initiation of treatment for RB.

This is a preview of subscription content, access via your institution.

Availability of data and material

Data is available with the authors.

References

  1. 1.

    Cassoux N, Lumbroso L, Levy-Gabriel C et al (2017) Retinoblastoma: update on current management. Asia Pac J Ophthalmol (Phila) 6:290–295

    Google Scholar 

  2. 2.

    Abramson DH, Shields CL, Munier FL, Chantada GL (2015) Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmol 133:1341–1347

    Article  Google Scholar 

  3. 3.

    Shields CL, Mashayekhi A, Au AK et al (2006) The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113:2276–2280

    Article  Google Scholar 

  4. 4.

    Shields CL, Manjandavida FP, Lally SE et al (2014) Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 121:1453–1460

    Article  Google Scholar 

  5. 5.

    Francis JH, Roosipu N, Levin AM et al (2018) Current Treatment of bilateral retinoblastoma: the impact of intraarterial and intravitreous chemotherapy. Neoplasia 20:757–763

    Article  Google Scholar 

  6. 6.

    Shields CL, Alset AE, Say EA et al (2016) Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before and during the intravitreal chemotherapy Era. J Pediatr Ophthalmol Strabismus 53:275–284

    Article  Google Scholar 

  7. 7.

    Berry JL, Kogachi K, Murphree AL et al (2019) A review of recurrent retinoblastoma: Children’s Hospital Los Angeles Classification and Treatment Guidelines. Int Ophthalmol Clin 59:65–75

    Article  Google Scholar 

  8. 8.

    Mallipatna AC, Gallie BL, Chévez-Barrios P et al (2017) Retinoblastoma. In: Amin MB, Edge SB, Greene FL et al (eds) AJCC cancer staging manual, 8th edn. Springer, Switzerland, pp 819–831

  9. 9.

    Shields CL, Mashayekhi A, Cater J et al (2004) Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 138:329–337

    Article  Google Scholar 

  10. 10.

    Francis JH, Levin AM, Zabor EC et al (2018) Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival. PLoS ONE 13:e0197081

    Article  Google Scholar 

  11. 11.

    Shields CL, Honavar SG, Shields JA et al (2002) Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120:460–464

    Article  Google Scholar 

  12. 12.

    Abramson DH, Gamell LS, Ellsworth RM et al (1994) Unilateral retinoblastoma: new intraocular tumours after treatment. Br J Ophthalmol 78:698–701

    CAS  Article  Google Scholar 

  13. 13.

    Abramson DH, Greenfield DS, Ellsworth RM (1992) Bilateral retinoblastoma. Correlations between age at diagnosis and time course for new intraocular tumors. Ophthalmic Paediatr Genet 13:1–7

    CAS  Article  Google Scholar 

  14. 14.

    Shields CL, Shelil A, Cater J et al (2003) Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 121:1571–1576

    Article  Google Scholar 

  15. 15.

    Gelaw Y, Shoukry SM, Othman IS (2016) Unusually very late-onset new growth of intraocular retinoblastoma: a case report and review of literature. Am J Ophthalmol Case Rep 5:130–133

    Article  Google Scholar 

  16. 16.

    Ytteborg J, Arnesen K (1972) . Late recurrence of retinoblastoma. Acta Ophthalmol (Copenh) 50:367–374

    CAS  Article  Google Scholar 

  17. 17.

    Dalvin LA, Bas Z, Tadepalli S et al (2020) Risk factors for tumor recurrence following primary intravenous chemotherapy (Chemoreduction) for retinoblastoma in 869 Eyes of 551 patients. J Pediatr Ophthalmol Strabismus 57:224–234

    Article  Google Scholar 

Download references

Funding

This work is supported by Hyderabad Eye Research Foundation, Hyderabad, India, and The Operation Eyesight Universal Institute for Eye Cancer, Hyderabad, India.

Author information

Affiliations

Authors

Contributions

VSV and YP were responsible for data collection and critical review of the manuscript. AM was responsible for data analysis and critical review of the manuscript. SK was responsible for the concept and formulation of the work, data interpretation, and drafting of the manuscript.

Corresponding author

Correspondence to Swathi Kaliki.

Ethics declarations

Conflict of interest

No conflicting relationships exist for any author. No conflicts of interest exist for any author. This work involved demographic and clinical information of human participants. All procedures performed were in accordance with the ethical standards of the institutional ethics committee and adhered to the Declaration of Helsinki, 1964 and its later amendments or comparable ethical standards. Informed consent has been obtained from all study participants.

Consent to participate

Consent to participate was obtained from the patients.

Consent for publication

Consent for publication was obtained from the patients.

Ethical standards

Research involved demographic and clinical information of human participants. All procedures performed were in accordance with the ethical standards of the institutional ethical standards of the institutional ethics committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Ethics approval

This study has been approved by the Institute Ethics Committee.

Gels and Blots/Image Manipulation

No image manipulation has been done.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Support provided by The Operation Eyesight Universal Institute for Eye Cancer (SK) and Hyderabad Eye Research Foundation (SK), Hyderabad, India. The funders had no role in the preparation, review, or approval of the manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kaliki, S., Vempuluru, V.S., Priya, Y. et al. Risk factors for recurrent retinoblastoma after intravenous chemotherapy. Int Ophthalmol (2021). https://doi.org/10.1007/s10792-021-01759-4

Download citation

Keywords

  • Eye
  • Tumor
  • Cancer
  • Retinoblastoma
  • Recurrence